-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA ANNOUNCES NEW EXERCISE CAPACITY DATA FROM THE IMPALA-2 PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

Reuters·05/18/2026 18:55:00

Please log in to view news